Pediatrics Doctors in Berwyn Heights, MD Accepting Medicare
5 Pediatrics doctors found. Showing 1 - 5
 Dr. James Burgin, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6201 Greenbelt Rd, L1-3, Berwyn Heights, MD 20740 Phone: 301-345-2270 Fax: 301-345-7149 |
Dr. Melvin Feldman, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6201 Greenbelt Rd, L1-3, Berwyn Heights, MD 20740 Phone: 301-345-1900 Fax: 301-345-7149 |
 Dr. Margaret Delaney, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6201 Greenbelt Rd, L1-3, Berwyn Heights, MD 20740 Phone: 301-345-1900 Fax: 301-345-7149 |
Dr. Tsega Demmeke, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6201 Greenbelt Rd, Suite L 1, Berwyn Heights, MD 20740 Phone: 301-345-1900 Fax: 301-345-7149 |
Chuntung Changchien, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 8824 Cunningham Dr Ste E, Berwyn Heights, MD 20740 Phone: 301-345-5311 Fax: 301-982-5065 |
News Archive
Comprehensive collection of human genomic variants now available in Kaviar database
The Institute for Systems Biology (ISB) and the Inova Translational Medicine Institute (ITMI) announced today a new release of Kaviar, the most comprehensive collection of human genomic variants currently available to the public.
Janssen-Cilag International's European MAA for ZEFTERA: CHMP adopts negative opinion
Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on its Marketing Authorisation Application (MAA) for the antibiotic ZEFTERA(TM) (ceftobiprole medocaril), for the treatment of complicated skin and soft tissue infections.
National Institute of General Medical Sciences now offers range of online products
As the heat index rises, one thing remains at zero—the cost of the engaging and informative educational materials produced by the National Institutes of Health.
HGS receives Complete Response Letter from FDA for ZALBIN drug
Human Genome Sciences, Inc. today announced that, as expected, it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for 900-mcg ZALBIN (albinterferon alfa-2b, known in Europe as JOULFERON®) dosed every two weeks for the treatment of chronic hepatitis C.
› Verified 4 days ago
Pediatrics
Internal Medicine
Family Medicine
Obstetrics & Gynecology
Cardiovascular Disease
Psychiatry & Neurology
Otolaryngology
Dermatology